BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition

Allergan, an AbbVie company, today announced that the U.S. Food and Drug Administration has approved BOTOX ® for the treatment of detrusor overactivity associated with a neurologic condition in …
( read original story …)

---